To address the limitation, we suggest a nanosuspension‐based immune modulation strategy that can induce high population of antigen‐specific T cells and relieve the IDO‐related immunosuppression in both TME and TDLN, through an assemblable immune modulating suspension (AIMS) that can not only form in situ depot in tumor bed but also migrate efficiently into TDLN. Here, IDO1 is linked to neoplasm.